Macrophages tailor their function according to the signals found in tissue microenvironments, assuming a wide spectrum of phenotypes. A detailed understanding of macrophage phenotypes in human tissues is limited. Using single-cell RNA sequencing, we defined distinct macrophage subsets in the joints of patients with the autoimmune disease rheumatoid arthritis (RA), which affects ~1% of the population. The subset we refer to as HBEGF + inflammatory macrophages is enriched in RA tissues and is shaped by resident fibroblasts and the cytokine tumor necrosis factor (TNF). These macrophages promoted fibroblast invasiveness in an epidermal growth factor receptordependent manner, indicating that intercellular cross-talk in this inflamed setting reshapes both cell types and contributes to fibroblast-mediated joint destruction. In an ex vivo synovial tissue assay, most medications used to treat RA patients targeted HBEGF + inflammatory macrophages; however, in some cases, medication redirected them into a state that is not expected to resolve inflammation. These data highlight how advances in our understanding of chronically inflamed human tissues and the effects of medications therein can be achieved by studies on local macrophage phenotypes and intercellular interactions.
INTRODUCTION
Macrophage plasticity provides tailored homeostatic, immunol ogic, and reparative mechanisms in a wide range of tissues (1, 2) . Their transcriptional, epigenetic, and functional versatility allow macrophages to conform to tissue and diseasespecific factors, resulting in phenotypes indicative of the type of tissue and physiologic state (3) (4) (5) (6) (7) (8) (9) . Macrophages are a unifying feature in chronic human diseases such as atherosclerosis, autoimmunity, and granulomas (2, 10, 11) ; however, little is known about macro phage phenotypes in the context of human tissue pathologyparticularly at singlecell resolution. Furthermore, although in vitro studies have provided valuable insights into the range of macro phage polarization states (12, 13) , the relevance of these well characterized responses has been difficult to document in human tissues.
A precise understanding of human tissue macrophages may enable more effective therapeutic decisions for inflammatory diseases, for which it has often been difficult to discern which molecular pathway to target. For example, interleukin17 (IL17) and interferon (IFN) have been implicated in the patho physiology of inflammatory bowel disease, yet blockade of these factors has produced variable results and, in some cases, worsens disease activity, whereas anti-tumor necrosis factor (TNF) therapies are commonly effective (14) . Nonsteroidal antiinflammatory drugs (NSAIDs) treat pain and components of inflammation in the autoimmune disease rheumatoid arthritis (RA), but for unclear reasons, NSAIDs do not curb joint erosion (15) , whereas antiTNF therapies have proven highly effective on both fronts. Macrophages are innate immune cells common to most tissues and highly malleable to microenvironmental factors, suggest ing that they could function as indicators of distinct pathologic pathways in affected tissues and also serve as targets for tailored treatments in a specific disease. Furthermore, medications can be used to repolarize macrophages into states that actively resolve pathologic responses, as is now being developed for cancer treat ment (16, 17) . To develop such therapeutics for autoimmune and inflammatory conditions, an indepth classification of tissue macrophages is needed, along with an understanding of how medications will redirect them as they concurrently react to the tissue environment and pathologic signals.
In the chronically inflamed RA joint tissue, macrophages are a source of TNF, a wellestablished driver of RA (18) (19) (20) (21) . However, the precise nature and variety of macrophages within the RA synovium is not yet defined. Furthermore, the cumulative effects of intercellular interactions and medications on macrophage responses in RA tissue remain to be determined.
RESULTS

Single-cell RNA sequencing detects HBEGF + inflammatory macrophages in RA synovial tissue
To define the spectrum of macrophage phenotypes in a human tissue affected by autoimmunity, we sorted CD14 + cells from the syn ovial tissue of 10 patients with RA and applied singlecell RNA sequencing (scRNAseq, CELSeq2), as previously reported (22) . Two tissue from patients with osteoarthritis (OA) were also included to iden tify cell subsets that may be found in low frequency in RA tissues, but higher in other disease states. After stringent quality control filtering, 940 CD14
+ single cells clustered into four major CD14 + syn ovial cell subsets based on canonical correlation analysis (CCA) as described ( Fig. 1A) (22) . Because the cells from all four clusters expressed the myeloid lineage genes CD68, CD163, C1QA, and CD14 ( fig. S1A ), we designated these cells macrophages rather than dendritic cells (7, 23) . Clusters 1 and 2 contained the majority of the CD14 + cells (45 and 30%, respectively) and the largest number of genes that dis tinguished them from the other clusters (Fig. 1B and fig. S1B ; 125 and 193 genes >2fold expression difference, respectively). For cluster 1, this included the proinflammatory genes NR4A3 (nuclear receptor sub family 4 group A member 3), PLAUR (plasminogen activator, urokinase receptor), and CXCL2 and the growth factors HBEGF (heparin binding EGFlike growth factor) and EREG (epiregulin) (hereafter referred to as "Cluster 1 HBEGF + ") (24, 25) . Cluster 2 was marked by a subset of genes involved in phagocytosis, such as ITGB5, ADORA3, and MERTK (Fig. 1B) (26) . Cluster 3 appeared less well defined by positive markers, whereas cluster 4 highly expressed a series of IFN stimulated genes such as IFI6 and IFI44L and herein is referred to as the "IFN/STAT" cluster ( Fig. 1B and fig. S1B ).
To estimate the abundance of each macrophage cluster in RA tissues, we sorted CD14 + synovial cell populations from 16 patients with RA and 13 patients with OA and analyzed them using bulk RNAseq (~1000 CD14 + cells from each patient) as previously re ported (22) . We detected 1726 genes with distinct expression pat terns between the two disease states [ Fig. 1C , false discovery rate (FDR) adjusted P < 0.1], with most of the variation in the samples associ ated with disease diagnosis (fig. S1C ). We detected enrichment of genes and pathways associated with RA disease, such as elevated TNF, STAT1, and STAT4 expression and heightened TNF, IFN, and in flammation pathways [gene set enrichment analysis (GSEA)] in RA CD14 + cell populations (Fig. 1C , left and right panel, respectively) (27) (28) (29) (30) . Overlaying the RA versus OA comparison with markers from each of the singlecell clusters, we found that genes defining the cluster 1 HBEGF + and cluster 4 IFN/STAT (signal transducer and activator of transcription) macrophages were consistently more abundant in RA CD14 + populations, suggesting an enrichment of these macrophage subsets in RA (Fig. 1D) . Furthermore, the cluster 1 HBEGF + subset was the predominant CD14 + subset found in the majority of RA tissues ( fig. S1D ; 7 of 12 RA tissues). Cluster 2 genes were found in higher ratios in OA tissues, whereas cluster 3 markers showed no consistent association with either disease (Fig. 1D) . RA CD14 + populations were also found to be positively enriched in gene sets generated from cluster 1 HBEGF + and cluster 4 IFN/STAT while negatively enriched in cluster 2 genes (GSEA, FDR adjusted P < 0.001) (Fig. 1E, light gray bars) .
To identify factors from the microenvironment that shape syn ovial macrophage phenotypes, the synovial CD14 + singlecell gene sets were compared to human blood-derived macrophages activated by diverse stimuli (Fig. 1E , colored bars, ranked gene lists). Cluster 1 HBEGF + and cluster 4 IFN/STAT genes were positively enriched in proinflammatory M1like macrophage genes induced by TNF and anticorrelated with the IL4 driven M2 antiinflammatory pheno type, indicating that these two macrophage subsets are activated by proinflammatory factors (Fig. 1E , red versus yellow bars). Con versely, cluster 2 genes were negatively enriched for TNFinduced inflammatory genes, suggesting that cluster 2 cells are not driven by classic proinflammatory factors. Cluster 2 genes were also not en riched for the IL4-induced M2 antiinflammatory polarization program, thereby potentially indicating a distinct macrophage pheno type tailored to factors in the synovial tissue environment. The limited number of cluster 3 positive markers did not significantly associate with any of the stimulated macrophage states. As the most abundant cell type in the RA synovium (31) (fig. S2A ), synovial fi broblasts can evoke large shifts in macrophage gene expression pro files (32) . The combination of synovial fibroblasts together with TNF (TNF + Fib) generated a macrophage phenotype that aligned closer to cluster 1 HBEGF + macrophages than the other stimuli (Fig. 1E ). This was unlikely due to a simple additive effect that exacerbated the TNF response, as synovial fibroblasts and TNF can induce opposing effects, for example, in cluster 4 genes (Fig. 1E) . Thus, we posited that the abundant cluster 1 HBEGF + macrophages from affected human tissue are driven by a combination of tissuespecific factors from resident synovial fibroblasts and inflammatory signals such as TNF.
Consistent with an enrichment in RA, the CD14 + cluster 1 HBEGF + single cells expressed high amounts of classic inflammatory genes like IL1B and low amounts of M2associating genes such as MERTK (Fig. 1 , B and F) (13) . However, cluster 1 HBEGF + cells were also distinctively high in the expression of genes such as HBEGF and PLAUR (Fig. 1F) , which have largely been reported as marking anti inflammatory phenotypes or cells derived from a combination of pro and antiinflammatory triggers (33, 34) . Considering the unique cluster 1 singlecell phenotype and consistent with elevated HBEGF expression across RA CD14 + synovial cell populations (Fig. 1G ), we designate cluster 1 macrophages as "HBEGF + inflammatory macrophages". In an independent study using a dropletbased scRNAseq platform (Dropseq) applied to synovial tissues from five patients with RA ( fig. S2A ), we detected an abundant macrophage subset with considerable overlap of marker genes with HBEGF + inflammatory macrophages ( fig. S2B, 62% ), including HBEGF, PLAUR, IL1B, and CREM ( fig. S2C ) (31) . Overlap with the other CD14 + singlecell clusters was less obvious, potentially due to the different technologies and computational and analysis pipelines or to the lower number of samples used in the previous study. Nonetheless, through independent singlecell platforms and patient cohorts, synovial macrophages of the HBEGF + inflammatory macro phage phenotype can be robustly detected in human tissue affected by RA.
Tissue-resident synovial fibroblasts shape HBEGF + inflammatory macrophages To further define the HBEGF + inflammatory phenotype, we com pared the transcriptome of macrophages exposed to TNF and syn ovial fibroblasts versus TNF alone. In a Transwell coculture system where both cell types were exposed to TNF (24 hours, n = 4 donors), synovial fibroblasts altered the expression of 3709 macrophage genes (FDR adjusted P < 0.1) (Fig. 2A) . The majority of fibroblastmediated effects opposed the direction of gene expression change induced by TNF alone ( Fig. 2A ; 69% of fibroblast effects anticorrelated with TNF effects, upper left and lower right). These changes included downregulation of TNFinducible proinflammatory S3B ). From these data, we hypothesized that PGE 2 mediated a considerable portion of the synovial fibroblast effect on macrophages. TNFstimulated synovial fibroblasts (Fig. 2F , F + T) produced large amounts of PGE 2 , whereas macrophages produced no detectable PGE 2 irrespective of TNF expo sure ( Fig. 2F ; M and M + T). Furthermore, induction of HBEGF + genes such as PLAUR and HBEGF in bloodderived macrophages was recapitulated by exogenous PGE 2 and TNF, with the fibroblast mediated induction blocked by the cyclooxygenase (COX) enzyme inhibitor naproxen (Fig. 2, G and H, respectively) . Upon the combina tion of TNF and PGE 2 , the increased transcription of HBEGF and PLAUR associated with chromatin opening in their promoter regions, as detected by ATACseq (assay for transposase accessible chromatin seq) and FAIREqPCR (formaldehydeassisted isolation of regulatory elementsqPCR) (Fig. 2, I and J, respectively, and fig. S3C ).
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These data suggest that in the RA synovium, chronic exposure to the proinflammatory environment results in heightened synovial fibroblast production of prostaglandins that, together with inflam matory factors, drive macrophages toward a state distinct from classical M1 and M2 polarization. Distinct transcriptional regulators, cell surface markers, metabolic pathways, and chromatin modifications mark this HBEGF + inflammatory state.
HBEGF + inflammatory macrophages promote fibroblast invasiveness
To examine how HBEGF + inflammatory macrophages may affect RA pathology, we focused on their intercellular relationship with syn ovial fibroblasts. In an RNAseq analysis, exposure to HBEGF + in flammatory macrophages altered 855 synovial fibroblast genes (FDR adjusted P < 0.1), including induction of IL11, LIF, CSF3 [granulocyte colonystimulating factor (GCSF)], IL33, IL6, and PLAU (Fig. 3A) . Pathway analyses revealed an upregulated epidermal growth factor receptor (EGFR) response in the fibroblasts, observed with two gene sets (one induced by EGFR ligands and a second blocked by an EGFR inhibitor) (Fig. 3B) . Similar to the gene expression changes, we also detected increased GCSF and IL33 protein in culture supernatants in the presence of HBEGF + macrophages (Fig. 3C) . The increased production of neutrophil chemoattractants and growth factors, such as GCSF, led us to investigate how HBEGF + inflammatory macro phages may affect neutrophils. Supernatants from cocultures of HBEGF + macrophages and synovial fibroblasts resulted in elevated neutrophil counts in a culturebased viability assay ( fig. S4A ). As synovial fluid from inflamed RA joints is characterized by elevated neutrophils (36, 37) , increased production of neutrophil chemoat tractant and survival factors in the tissue may support neutrophil recruitment and viability as they transit into the synovial fluid. Last, we found that the expression of GCSF and IL33 was sensitive to EGFR inhibition (AG1478, AG) (Fig. 3D) , further implicating EGFR in volvement in this inflammatory macrophagefibroblast crosstalk system and identifying an additional therapeutic avenue to target HBEGF + macrophagedriven inflammation. To further understand the EGFR responses in the synovial fibro blasts, we investigated the expression of EGF ligands and EGFR subunits in both the macrophages and fibroblasts in the coculture system and in primary synovial macrophages and fibroblasts. Synovial fibroblasts expressed only trace amounts of seven EGF ligands with no change in response to TNF and HBEGF + macrophages ( fig. S4B ). In contrast, macrophages induced HBEGF and a second EGF ligand EREG upon combined exposure to TNF and synovial fibroblasts ( fig. S4B ). Although EREG expression in the bloodderived macro phage system was higher than that of HBEGF ( fig. S4B ), the RA pa tient synovial macrophages exhibited considerably higher expression of HBEGF (Fig. 1B) . For EGFR expression, synovial fibroblasts ex pressed two subunits (EGFR and ERBB2), whereas neither blood derived macrophages nor RA synovial macrophages expressed EGFR subunits ( fig. S4, C and D) . Considering these data, we posit that synovial fibroblast EGFR responses arise in response to EGF ligand expressed by fibroblastentrained inflammatory HBEGF + macrophages. EGFR signaling is a robust regulator of fibroblast motility (38) . In RA, synovial fibroblasts contribute to the invasion and destruc tion of cartilage and bone by synovium (39) (40) (41) (42) . Thus, we next test ed whether a heightened EGF response influenced the migration of synovial fibroblasts through extracellular matrix. Preincubation of fibroblasts with TNF and macrophages induced a pronounced in crease in fibroblast invasiveness that was mitigated by EGF receptor inhibition (Fig. 3E and fig. S4E ). These data demonstrate that the HBEGF + macrophagedependent EGFR response may promote patho logic fibroblastmediated and pannusassociated tissue destructive behaviors in RA joints.
RA medications target HBEGF + inflammatory macrophage polarization
We next examined how clinically effective RA medications affect the polarization of HBEGF + inflammatory macrophages, using human blood-derived macrophages exposed to TNF and synovial fibro blasts. In comparison to macrophages exposed only to TNF, the presence of synovial fibroblasts substantially altered the effects of most medications ( fig. S5A ). For example, the majority of auranofin targets were lost when macrophages were polarized toward the HBEGF + phenotype (1300 genes, 67%) ( fig. S5A , blue versus yellow). In contrast, several of the medications gained more than 1000 gene targets in HBEGF + inflammatory macrophages, including naproxen and leflunomide (A77, an active leflunomide metabolite) ( fig. S5A) . In macrophages exposed only to TNF, induction of nuclear factor B (NFB) target genes was reversed by auranofin and several other medications, but not by naproxen and leflunomide ( fig. S5B ). However, , and the EGFR inhibitor (AG). n = 3 donors. *P < 0.05, **P < 0.01, and ***P < 0.001 by paired Student's t test, respectively.
synovial fibroblastmediated suppression of Myc target genes in TNFinduced macrophages was reversed by naproxen and leflunomide ( fig. S5C ). Thus, synovial fibroblasts alter the response of macrophages to medications used to treat patients with RA. Several medications reversed a large portion of fibroblastinduced effects (~1000 genes), suggesting that the efficacy of these treatments in the clinic could involve a suppression of HBEGF + inflammatory macrophages in the RA synovium (Fig. 4A, black bars) . This in cluded leflunomide (A77), dexamethasone (steroid), naproxen, and triple therapy (Tri, hydroxychloroquine + sulfasalazine + metho trexate) (Fig. 4A, black bars) . Naproxen inhibits COX enzyme mediated prostaglandin production and, in our assay, affected the majority of genomewide fibroblastmediated effects (~80%) (Fig. 4A  and fig. S5, A to D) , further supporting the idea that prostaglandins are a dominant fibroblast product driving HBEGF + inflammatory mac rophages. The inhibition of HBEGF + inflammatory macrophages by various medications resulted in at least two functionally distinct states. Naproxen, for example, blocked the prostaglandin arm driving HBEGF + inflammatory macrophages, but still permitted TNF polarization of the macrophages toward an M1like proinflamma tory phenotype, which presumably also functions pathologically in RA synovium ( fig. S5, A and D) . In contrast, medications like dexa methasone were capable of largely blocking both the TNF and PGE 2 responses ( fig. S5A ), driving macrophages closer to an untreated/ naïvelike phenotype. These results highlight the importance of un derstanding variations in macrophage phenotypes after treatment, particularly in complex tissue settings where multiple factors could redirect macrophages toward a differing yet pathologic state.
RA medications target the HBEGF + macrophage-synovial fibroblast axis in patient samples
To study the therapeutic targeting of HBEGF + macrophages in RA joints, we directly assayed synovial tissue from patients with RA (43, 44) that contained extensive lymphocyte infiltration (45, 46) (table S1; n = 8). Specifically, in an ex vivo tissue assay, synovium was dissociated into cell suspensions (47) and cultured with U.S. Food and Drug Administration (FDA)-approved RA medications (Fig. 4B) . Similar to the seminal assays that laid the precedent for effective antiTNF therapies in RA (48-50), exposure to antiTNF antibodies (adalimumab) suppressed production of the inflammatory mediator IL1 (Fig. 4C) . Furthermore, in this assay, the Janus kinase (JAK) inhibitor tofacitinib imparted notable reductions in genomewide IFN responses and secreted protein for the JAK/STAT target CXCL10 (IP10) (Fig. 4C) . Antiinflammatory therapies such as antiTNF, tofacitinib, and dexamethasone inhibited the HBEGF + inflammatory synovial macrophage cluster 1 gene set (Fig. 4D) . Conversely, the panel of antiinflammatory medications upregulated the cluster 2 gene set (with one exception, A77/leflunomide) (Fig. 4D) , including antiinflammatory genes MERTK, TGFBI, and MARCO (Fig. 1F and  fig. S5E ) (51) (52) (53) . Tofacitinib was the most potent inhibitor of the cluster 4 IFN/STAT gene set (Fig. 4D) , further implicating a robust JAK/STAT response in this RAassociated macrophage subset. The JAK/STAT response in cluster 4 was induced by naproxen, as indicated by an enrichment of cluster 4 genes and elevated CXCL10/ IP10 protein production in naproxentreated RA synovial cells (Fig. 4, D and E) . This was associated with a reduction in prosta glandin production upon treatment with naproxen ( Fig. 4F) and is in accord with the established inhibitory effects of prostaglandins on IFN responses (54-56).
To test for evidence of the crosstalk module we identified between HBEGF + inflammatory macrophages and synovial fibroblast EGFR responses, we further examined the effects of naproxen in our tissue explant system. Here, we found that naproxen blocked prostaglandin production and reduced HBEGF expression and GCSF (CSF3) protein secretion by the RA synovial explants (Fig. 4, F to H) , indicating a decoupling of the macrophagefibroblast circuit. Naproxen did not interfere with TNFmediated effects in the ex vivo tissue assay, as indicated by the lack of change in IL1 protein production (Fig. 4I) . TNF blockade with adalimumab in the ex vivo tissue assay, however, was effective in blocking both HBEGF expression and IL1 protein production (Fig. 4, C and D) , thereby derailing generation of both the HBEGF + inflammatory macrophages and proinflammatory M1like macrophages ( fig. S5F) .
To directly assay EGFRdependent fibroblast gene expression changes consistent with HBEGF + inflammatory macrophage influence, we introduced a therapeutic EGFR inhibitor not currently used to treat RA into the ex vivo assay. The EGFR inhibitor reversed the majority of the synovial fibroblast gene expression effects elicited by HBEGF + inflammatory macrophages (77%), including a suppression of CCL20, CSF3, LIF, IL33, IL11, and PLAU (Figs. 3A and 4J ). Together, these data provide evidence within patient tissues for the crosstalk module we identified between HBEGF + inflammatory macrophages and tissueresident fibroblasts and furthermore indicate that blockade of EGFR responses may provide a nonimmuno suppressive therapeutic approach for RA.
DISCUSSION
Challenges in treating autoimmune and inflammatory disorders have led to strategies including administering medications sequentially until one is found to improve clinical symptoms. In an effort to improve a priori knowledge of which medication will be most effective, we have taken into consideration the cellular interactions in affected tissues, identifying a population of HBEGF + inflammatory macrophages in inflamed RA joints and delineating their deterministic tissueresident and diseasespecific factors. Furthermore, we have identified medications that successfully interfere with the generation of these macrophages and the support they provide toward fibroblast invasiveness, which contributes to irreversible joint destruction in RA.
The crosstalk mechanisms and functional output between macrophages and fibroblasts in the RA tissue environment differ from other pathologic states driven by these two cell types. In fibrosis, macrophages and fibroblasts drive excessive collagen deposition, blocking tissue function in part by static physical barriers rather than invasive and erosive behaviors (2, 57, 58) . In RA, fibroblast products such as prostaglandins combine with chronic inflammatory signals such as TNF to polarize macrophages into a state that is distinct from inflammatory M1, antiinflammatory wound healing M2, and profibrotic transforming growth factor-expressing macrophages. The RAenriched HBEGF + inflammatory macrophages produce a defined subset of inflammatory products such as IL1 and the EGF growth factors HBEGF and epiregulin. Because HBEGF + inflamma tory macrophages subsequently induce invasiveness in synovial fibro blasts, we classify them as "proinvasive macrophages."
Although leukocytederived growth factors have emerged as critical components in tissue homeostasis and repair (1, 59) , our data uncovered a pathologic correlate. In the RA tissue environment, macrophageproduced EGF ligands lead to EGFRdependent synovial fibroblast invasiveness and GCSF production concomitant with enhanced neutrophil accumulation-dominant features of RA joint pathology (36, 37, 40) . In inflammatory arthritis in vivo models, disease progression is driven by EGF ligands, EGF receptor activity, and the enzyme iRhom2, which mediates release of both TNF and HBEGF from immune cells (60) (61) (62) (63) . Our data provide relevance to these findings in human disease and a mechanistic understanding of the cellular crosstalk involving growth factors in RA joints. TNF and HBEGF have been implicated as pathologic drivers of kidney disease in the autoimmune condition lupus (64, 65) . Thus, linked TNF and EGFR responses may be a unifying and targetable feature in tissues affected by disparate autoimmune conditions. Using perturbations relevant to human disease, namely, FDA approved medications, we have detailed the disruption of intercellular interactions in patient samples and the resulting cellular phenotypes, thereby gaining insights into the complex consequences of medications on RA joint tissue. Our data yielded insights into a longstanding question of why antiinflammatory COX inhibitors known as NSAIDs are not "disease modifying" in RA (15) . Our data suggest that NSAIDs, like naproxen, block the prostaglandinmediated arm in HBEGF + inflammatory macrophage polarization, but still permit macrophage TNF responses. Thus, NSAID therapy in RA likely redirects HBEGF + inflammatory macrophages toward a classic proinflammatory M1 like phenotype, which would presumably perpetuate inflammation, albeit through a different pathway. In that regard, NSAIDs may best be used in combination with medications like antiTNFs to most effectively target HBEGF + inflammatory macrophage polarization. However, COX inhibition by naproxen may also prove problematic in the other RAenriched macrophage phenotype, by inducing the cluster 4 IFN/STAT response, consistent with the previously documented and robust suppression of IFN responses by prosta glandins (54, 56) . Thus, NSAIDs are permissive of pathologic responses for two RAenriched macrophage phenotypes. These data speak to the greater need to understand tissue microenvironment factors that polarize macrophages and how, in the presence of ther apeutics, the intercellular communication networks are rewired and subsequently repolarize macrophages into states that either resolve or perpetuate pathology.
Limitations of this study include the inability of an in vitro coculture system to fully recapitulate all aspects of a macrophage phenotype found within human synovial tissue. Furthermore, although an in vitro assay can measure fibroblast invasiveness, a precise understanding of how this translates into fibroblast activity within patient synovial tissue is limited. The in vitro and ex vivo drug assays have limitations related to differences in how medications are processed in cultured cells versus the human body, including how drugs are metabolized in the intestinal tract and their stabiliza tion upon binding to carrier proteins in the blood, among others. Last, the analysis of macrophage responses in the ex vivo tissue assay is derived from mixed synovial cell RNAseq data and thereby may be incorporating expression changes from other synovial cell types.
Along with the seminal synovial explant assay that provided the rationale for use of TNF therapies in RA (48), our work supports the implementation of ex vivo assays to better understand and treat patients with autoimmune and inflammatory disorders. Specifically, in addition to detecting genomewide established targets of antiTNF and tofacitinib therapies, our RA patient ex vivo synovial tissue bioassay provides a human and diseaserelevant system that unmasked the interconnectivity and drug responsiveness of the synovial macrophagefibroblast interaction we identified. Human tissuebased therapeutic testing for autoimmune conditions may offer guidance in defining personalized therapies, as the intercellular networks driven by the unique cellular composition in a patient's tissue may be exploited in ex vivo assay to indicate how these cells crossregulate after treatment with a medication and collectively shape new tissue responses. For RA, this could be accomplished with the expanding use of synovial biopsies (21, 22, 66) and ultimately with the identification of circulating biomarkers that correlate with tissuebased assays. Last, effective blockade of the macrophage induced fibroblast response in the RA tissue ex vivo assay with an EGFR inhibitor developed for cancer warrants testing of this as a new treatment direction, particularly because it may not broadly suppress the immune system, unlike many of the current RA medications.
MATERIALS AND METHODS
Study design
The objectives of this project were to study macrophage phenotypes that are enriched in the joints of patients with the autoimmune disease RA using scRNAseq and to understand how medications affect these phenotypes using ex vivo tissue assays. An in vitro coculture model system was used to understand how resident synovial cell types and pathologic cytokines drive macrophage phenotypes and drug responses. Synovial tissue from patients treated for RA and OA was used, in addition to blood from healthy human donors. All patients were consented under institutional review board (IRB) -approved studies at Hospital for Special Surgery or clinical sites in the Accelerating Medicines Partnership (AMP) consortium. Inclusion and exclusion criteria for patients with arthritis were based on stan dard clinical diagnostic criteria, such as the ACR 2010 RA criteria. Perceived outliers in sequencing datasets from the coculture system remained in the analyses upon application of surrogate variable analysis by svaseq version 3.26.0. The number of human donor bloodderived macrophage biologic replicates depended on the robustness of the response for each type of assay and therein the variability across donors: For robust assay responses, typically about n = 4 donors were used, whereas for assays with higher variability, n = 8 donors were used. Individual subjectlevel data are provided in data file S1.
Patient recruitment and CD14
+ synovial cell sorting for RNA-seq The multicenter RA/SLE (systemic lupus erythematosus) Network of the AMP consortium enrolled individuals meeting the ACR 2010 RA classification according to protocols approved by the IRB at each site (22, 47) . Synovial tissues were collected from ultrasound guided biopsies or joint replacement surgery and viably frozen in CryoStor CS10 cryopreservation media (SigmaAldrich). At a central processing site, tissues were dissociated and cells were FACS (fluorescence activated cell sorting)-sorted (BD FACSAria Fusion) into fibroblast, macrophage, B cell, and T cell populations. Macrophages were sorted on the basis of CD14 + CD45 + cell surface expression. For bulk RNAseq on CD14 + synovial cell populations, ~1000 cells were sorted directly into RNeasy RLT lysis buffer (Qiagen). For CD14 + synovial scRNAseq, ~100 live cells per patient were individually plated and lysed in 384well plates.
Bulk RNA-seq and scRNA-seq of sorted CD14 + synovial cells For bulk populations of cells, fulllength complementary DNA and sequencing libraries were generated using Illumina SmartSeq2 protocol (67) . Libraries were sequenced on a MiSeq System (Illumina) to generate 35-base pair, pairedend reads. scRNAseq was performed on sorted macrophage and synovial fibroblast using the CELSeq2 protocol (68) in 384well plates. Libraries were sequenced on a HiSeq 2500 (Illumina) in rapid run mode to generate 76-base pair, pairedend reads.
CD14
+ bulk RNA-seq read alignment and differential gene expression analysis Reads were aligned and quantified with STAR version 2.4.2a (69) against the GRCh38 genome and GENCODE Release 27 annotation, respectively. Differential expression analyses and batch correction were performed using DESeq2 (70) 
+ scRNA-seq read alignment and differential gene expression analysis RNAseq reads were aligned with STAR version 2.5.2b (69) to the hg19 reference genome. Transcript levels were quantified as CPM using the GENCODE Release 24 annotation. The singlecell gene expression matrix was clustered based on a CCA methodology (22) . Briefly, scRNAseq and bulk RNAseq datasets were integrated based on the highly variable genes that maximized the correlation between the two datasets. The correlated canonical variates were then used to construct a nearestneighbor network, thereby gener ating clusters that are verified to be present in the bulk data. Using the four clusters identified from the CCA method, the top 10 canonical coordinates were used to generate a Euclidean distance matrix for tdistributed stochastic neighbor embedding (tSNE) visualization using a perplexity parameter of 40. Positive and nega tive cluster markers were identified using the Wilcoxon rank sum test with a Bonferroni correction for multiple testing.
Pathway analysis
Gene lists were processed for GSEA (72) version 3.0 by taking the inverse of the FDR adjusted P value for each gene and multiplying it by the sign of the log 2 fold change relative to the baseline conditions. GSEA was run under the "prerank" mode with 1000 permutations for each of the gene sets available in MSigDB and ImmunSigDB version 5.2. Additional pathway analysis was performed using QIAGEN's Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, www.qiagen. com/ingenuity). Reported pathways were referenced as follows with the MSigDB systematic name in parentheses: TNF signaling via NFB (M5890), IFN response (M5913), IFN response (M5911), inflammation (M5932), Myc targets (M5926 and M5928), oxidative phosphorylation (M5936), translation (M11989), cell cycle (M543), induced by EGF (M2613), hypoxiainduced (M5891), IFNresponsive genes (M9221), EGFR inhibitor (M16010), and KEGG (Kyoto Encyclo pedia of Genes and Genomes) ribosome pathway (M189). Gene sets derived from the CD14 + synovial scRNAseq markers were composed of up to 500 genes that exhibited >0.5 log 2 fold change (positive marker) or <−0.5 log 2 fold change (negative marker genes) relative to all other clusters, sorted by their fold change.
Independent RA arthroplasty cohort analyzed by Drop-seq
In an independent analysis, we collected synovial tissue from five RA patients consented under Hospital for Special Surgery (HSS) RA Studies (IRB nos. 2014317 and 2014-233) during arthroplasty and synovectomy procedures. Tissues were dissociated into singlecell preparations, and all cells were run through a Dropseq protocol and sequenced on a HiS eq 2500 (Illumina) (31) . After cell and gene filtering (31), we applied Seurat version 2.3.0 to generate principal components analysis-based singlecell clusters, which were labeled on the basis of celltype markers. A total of 20,031 single cells were visualized using the tSNE implemen tation in Seurat using a perplexity parameter of 20 and 13 principal components. After identifying a macrophage cluster consistent with our previous results (4212 single cells), we reapplied Seurat and identi fied distinct subpopulations and visualized in tSNE space.
Cell culture for human blood-derived macrophages and synovial fibroblasts Human CD14 + monocytes were purified from leukocyte preparations purchased from the New York Blood Center and differentiated into bloodderived macrophages for 1 to 2 days in macrophage CSF (MCSF; 10 ng/ml) (PeproTech) and RPMI 1640 medium (Life Technologies)/10% defined fetal bovine serum (FBS) (HyClone). Cells were stimulated with recombinant human TNF (20 ng/ml) (PeproTech). Drug treatments were administered 15 min after TNF exposure to both the top and bottom wells of the Transwell system to achieve the stated final concentrations. After suspending in dimethyl sulfoxide according to the company's instructions, auranofin (SigmaAldrich) was added to cells at 500 nM, A77 1726 (Santa Cruz Biotechnology) was added at 50 M, Tyrphostin AG 1478 (SigmaAldrich) was added at 4 M, GW 627368X (Cayman Chemical) was added at 10 M, sulfasalazine (SigmaAldrich) was added at 3 M, hydroxychloroquine sulfate (SigmaAldrich) was added at 50 M, methotrexate (Cayman Chemical) was added at 110 M, tofacitinib citrate (Cayman Chemical) was added at 1 M (73), and Pam3CSK4 (InvivoGen) was added at 1000 g/ml. Dexamethasone (SigmaAldrich) and PGE 2 (SigmaAldrich) were first suspended in absolute ethanol and then added to cells (100 and 280 nM, respectively). Naproxen was suspended in RPMI 1640 supplemented with 10% FBS and then added to cells at a final concentration of 100 M. AntiTNF was provided as adalimumab and was added to cells at a final concentra tion of 50 g/ml.
Human synovial fibroblasts derived from deidentified synovial tissues of RA patients undergoing arthroplasty (HSS IRB no. 14033). Dissociated cells were plated in minimum essential medium (MEM)-based media up to 10 days, washing with media numerous times to remove dying blood cell components. Synovial fibroblasts at passages 4 to 6 were used for experiments. The diagnoses of RA were based on the ACR 2010 criteria. For Transwell culture experiments, synovial fibroblasts adhered to polyester chambers with 0.4m pores (Corning) and were suspended above the wells containing macrophages, with a fibroblasttomacrophage ratio of 1:16 on the basis of the size of the cells and their coverage of the culture well surface. The number of donors used for each experiment is listed in the figure legend and refers to unique donors for both the blood derived macrophages and the synovial fibroblast lines.
RNA-seq for human blood-derived macrophages and synovial fibroblasts
Total RNA was extracted using the RNeasy mini kit (Qiagen). TruSeq (nonstranded) sample preparation kits (Illumina) were used to purify poly(A) transcripts and generate libraries with multiplexed barcode adaptors. Singleend libraries were multiplexed, pooled, and sequenced using the Single Read Clustering with 50 or 100 cycles on an Illumina HiSeq 4000. Sequencing was performed by the Weill Cornell Medical College Genomics Resources Core Facility. RNAseq read alignment, quantification, differential testing, and pathway analysis were performed as described in previous sections.
Fibroblast invasion assay
Human synovial fibroblasts were plated in Transwell inserts with macrophages below as described above for the Transwell experiments. AG 1478 (SigmaAldrich) was added at 4 M for the 32hour coculture incubation. Fibroblasts were trypsinized and replated in 500 l of plain MEM with MCSF (10 ng/ml) at 0.1 × 10 6 cells per well into 24well Corning BioCoat Matrigel Invasion Chambers. Macrophages were resuspended in 750 l of plain MEM and seeded underneath invasion Transwells in the appropriate conditions. AG 1478 was added at a concentration of 4 M; after 18 hours, the fibroblasts were fixed for 10 min in icecold methanol and stained using crystal violet. Invasive fibroblast numbers were quantified via light microscopy.
Human RA ex vivo synovial cell assays For synovial cell cultures, RA patient synovial tissue was obtained from patients consented into the HSS FLARE study (IRB no. 2014-233). Tissues were digested with Liberase TL (100 g/ml, Roche) and deoxyribonuclease I (100 g/ml, Roche) for 15 min and passed through three 70 M cell strainers. Cells were then suspended in 1 ml of red blood cell lysis buffer (gift of J. Lederer, BWH) for 3 min followed by addition of RPMI 1640/10% FBS/1% glutamine to quench the reaction. Disaggregated synovial cells were plated in RPMI 1640/10% FBS/1% glutamine at 0.2 × 10 6 in 96well plates. Cells were treated with drugs at aforementioned concentrations for 24 hours. Supernatants and RNA were collected for Luminex experiments and qPCR, respectively. For RNAseq, the samples were multiplexed in eight samples per lane, 50 cycles, singleend reads, with TruSeq (Illumina) for library prep and a HiSeq 4000 (Illumina) in the Weill Cornell Medical College Genomics Resources Core Facility. RNAseq read alignment, quantification, differential testing, and pathway analysis were performed as described in previous sections.
Statistical analysis scRNAseq clusters were identified using a graphbased clustering method based on CCA (22) . Markers for different clusters were determined by Bonferronicorrected Wilcoxon rank sum tests imple mented in Seurat version 2.3.0. Visualization of intersecting sets was performed using UpSetR version 1.3.3 (74) . Testing for differ entially expressed genes from bulk RNAseq count data was performed using DESeq2 version 1.18.1 and surrogate variable analysis was performed using svaseq version 3.26.0, both run on the R version 3.3.2. All RNAseq significance levels are reported as FDR adjusted P values. Spearman and Pearson correlation analysis was performed using the seaborn statistical data visualization package version 0.8.1 run on Python version 3.6.4. Statistical significance of pathway anal ysis was reported as the normalized enrichment score and FDR adjusted P values determined from testing of 1000 permutations from GSEA version 3.0. Pathway z scores for upstream regulatory analyses were performed using IPA (QIAGEN). Data from in vitro and ex vivo as says are shown as mean ± SE unless stated otherwise. Twotailed paired t tests were performed for human sample-derived qPCR and ELISA data using GraphPad Prism version 5.04 for Windows. Luminex multiplex ELISA experimental data were tested for normality by the ShapiroWilk test with a significance threshold of P < 0.05 and were found to not follow a Gaussian distribution. Subsequent sta tistical analysis was thus performed by Wilcoxon signed rank tests, a nonparametric method, using GraphPad Prism.
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